COVAX was launched in April 2020 by the World Health Organization (WHO), the European Commission and France
COVAX was launched in April 2020 by the World Health Organization (WHO), the European Commission and France
During the regular trading day, both the S&P 500 and Dow pulled back from the record highs the indexes reached last week.
U.S. weapons maker Lockheed Martin Corp increased its outlook for 2021 sales and profit as it reported better-than-expected quarterly profits on Tuesday, helped by higher sales and profits at its unit which makes ships and helicopters. Though the maker of the F-35 fighter jet increased the midpoint of its full-year revenue outlook slightly to $68 billion, the estimate is below Wall Street's average estimate of $68.17 billion. One big potential dampener for defense companies' profits was removed earlier this month when U.S. President Joe Biden's proposed a flat defense budget for 2022 despite calls from progressive Democrats to reduce Pentagon spending.
Hasib Rahimi, 19, was jailed for 10 weeks for common assault.
Almonty Industries Inc. ("Almonty" or the "Company") (TSX: AII / OTCQX: ALMTF / Frankfurt: ALI.F) is pleased to announce that it has closed two previously anticipated private placements and secured binding commitments from existing shareholders and insiders on a convertible debenture. The private placements were agreed prior to the recent appreciation of the share price with existing European shareholders and the Company felt that it was appropriate to honor the price agreed from that time. The pricing was for 2,000,000 shares at $0.85 per share and 308,333 shares at $0.90 per share for a grand total of US$1,579,358. The Company has also procured an additional US$8,010,642m of executed binding commitments from existing shareholders and insiders, linked to an unsecured 5% p.a. convertible debenture with a $1.05 strike price. The binding funding trigger for this convert is 5 business days prior to the financial close of the KfW-IPEX US$75.1m loan which is now due to occur shortly.
A handful of startups are trying to find a new way to recycle used car batteries, using water, chemicals and electricity to produce lead instead of the hazardous, high-heat smelting that has been identified as the world's most polluting industry. One of the first to bring a new recycling technology to market is ACE Green Recycling Inc, which has developed a room-temperature process that turns lead from scrap batteries into ingots, its Singapore-based CEO Nishchay Chadha told Reuters. At its recycling plant in Ghaziabad, on the outskirts of the Indian capital New Delhi, the firm uses machines that run on electricity to refine lead components from scrap batteries into briquettes, which are then cast into ingots and sold to battery manufacturers.
Bloom Energy (NYSE: BE) has improved its margins significantly since its listing in 2018. Bloom Energy offers solid oxide fuel cells that use natural gas or biogas as an input fuel. By comparison, Plug Power (NASDAQ: PLUG) and Ballard Power (NASDAQ: BLDP) both offer proton exchange membrane (PEM) fuel cells that take hydrogen gas as an input fuel.
Biologist Richard Dawkins has had his Humanist of the Year honour revoked after making “bad faith” comments on trans lives.
Dublin, April 20, 2021 (GLOBE NEWSWIRE) -- The "Global Laboratory Product Purchasing Trends, 2020-2021" report has been added to ResearchAndMarkets.com's offering. Readers of one of the publisher's media partners were invited to participate in an online survey in September 2020 that centered on the state of their laboratories in 2020 and their expectations for 2021. The publisher has conducted similar studies among the same targeted respondents since 2012. Where applicable, the study presents year-over-year data to illustrate yearly trend developments. To qualify for survey participation, readers had to play a role in their laboratory's purchasing process, be familiar with their laboratory's product budgets, and represent a laboratory that either uses or plans to use products in one or more of the seven specified laboratory product categories: instruments, equipment, chemicals, reagents and kits, general lab supplies, plasticware, and glassware. A total of 211 decision makers qualified for and completed the survey, answering questions on purchases, budgets, top companies, and purchasing preferences. Respondents were segmented by type of laboratory: academic/government, biopharmaceutical, industrial, and clinical. This end-user survey polled researchers on their preferences in order to understand the laboratory product purchasing process and how that differs among the various organization types. The data collected was quantitative in respect to budgets and qualitative with reference to end-user trends such as budget expectations, brand selection preferences, purchasing process steps, evaluation and sourcing of lab products, recent and expected instrument and equipment purchases, frequency of price comparisons, funding trends, unmet needs, product purchasing preferences, and the impact of COVID-19 on lab shutdowns and spending. This survey provides companies with actionable and trending information from laboratory professionals that will help drive business strategies and develop growth expectations. For the purpose of this analysis, respondents identifying as manufacturing, environmental testing, chemical or petrochemical, and food, beverage, or agricultural are combined as industrial laboratories. Biotechnology, pharmaceutical, and contract research organization are combined as biopharmaceutical laboratories. State government and federal government laboratories are combined as government laboratories. Hospital laboratories and clinical reference laboratories fall under the clinical segment. Respondents indicated a wide range of job titles including researcher, scientist, investigator, director, manager, and technician. Key Topics Covered: 1. Research Objectives and Methodology Research ObjectivesResearch MethodologyRespondent Profiles 2. Executive Summary Key FindingsBudget ChangesLaboratory Product Budget Breakdown and TrendCOVID-19 Impact on LaboratoriesGrowth Opportunity Areas 3. Laboratory Product Purchases and Influential Factors of Selection Annual Comparison of Lab Product Information SourcesMost Frequently Used Information SourcesLab Product PurchasesAnnual Comparison of Product PurchasesLab Product Purchases by Organization TypeAnnual Comparison of Experience with Lab Product PurchasesProduct FeaturesProduct OriginManufacturer FeaturesOrdering and Shipment FeaturesComparing Market PricesPurchase ChannelsMost Frequently Used Purchase Channels 4. Purchasing Experience - Opportunity Analysis Purchasing Experience AspectsLaboratory Product Purchase Improvement AreasPurchasing Experience Aspect AssessmentPurchasing Experience Opportunity Areas 5. Laboratory Product Budgets and Growth Expectations 2020 Laboratory Product BudgetLaboratory Budget Breakdown and Trend2020 Laboratory Product Budget Breakdown and 2021 TrendLaboratory Product Funding SourcesLaboratory Product Funding Source Changes 6. Impact of COVID-19 on Laboratory Product Purchasing Trends COVID-19 Impact on LaboratoriesLaboratory Operating StatusLaboratory ShutdownCOVID-19 Impact on Q4 Spending 7. List of Exhibits For more information about this report visit https://www.researchandmarkets.com/r/2xd3yu CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Prime minister brands Irish Sea checks ‘ludicrous’ – despite negotiating and ratifying the agreement
The concept of a European Super League is based on unadulterated greed and will eclipse football’s everyday variety
Follow all the latest developments
Fifa president Gianni Infantino says his organisation strongly disapproves of a breakaway European Super League and has warned those clubs involved will have to “live with the consequences of their choice”. The news has sent shockwaves throughout football, with Uefa stating their desire to impose swift sanctions, which could include throwing Chelsea, Manchester City and Real Madrid out of this season’s Champions League and Arsenal and Manchester United out of the Europa League.
Royal fans were encouraged to see William and Harry chatting after saying their final farewells to their grandfather.
The S&P 500 is hovering near all-time highs, but that doesn't mean there aren't plenty of stocks still worth buying today. Many promising tech stocks now look cheaper after rising bond yields sparked a rotation from growth to value stocks, while many businesses that struggled during the pandemic could recover as vaccination rates rise.
Flowserve Corporation (NYSE: FLS), a leading provider of flow control products and services for the global infrastructure markets, today announced that it plans to release its results for the first quarter 2021 after the close of the New York Stock Exchange (NYSE) on Monday, May 3.
Turning Point Brands, Inc. ("TPB" or the "Company") (NYSE: TPB), a manufacturer, marketer and distributor of branded consumer products, including alternative smoking accessories and consumables with active ingredients, announced today a $8.7 million strategic investment in Docklight Brands, Inc., a pioneering consumer products company with celebrated brands including Marley Natural® cannabis and Marley™ CBD. In addition, TPB has obtained exclusive U.S. distribution rights for Docklight’s Marley™ CBD topical products. The investment into Docklight Brands’ Series A offering comes with certain follow-on investment rights.
COPENHAGEN, Denmark, April 20, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today a presentation by Jens Kringelum, PhD, Evaxion’s Director in Genomic Immuno-Oncology, at the 4th Neoantigen Summit Europe, being held virtually April 20-22, focusing on “AI in personalized cancer medicine”. The presentation described Evaxion’s recent improvement in determining cancer neoepitopes through measurement and prediction of peptide-MHC (pMHC) complex stability. The work, previously reported in Nature Communications, December 9, 2020, outlines data on the thermostability of pMHC, the biological context for antigen processing. The paper explains how this method can be used to generate new data to train AI models for prediction of T-cell epitopes, and demonstrates how this appears to be a significant improvement over AI models trained on traditional mass spectrometry ligand data. The data have already proved valuable in enabling Evaxion’s artificial neural networks to more readily predict the immunological behavior of certain peptide epitopes. Lars Wegner, CEO of Evaxion, said: “This exciting research is an important advancement in how we at Evaxion can train AI systems to make drug development more efficient. In particular, we believe the data indicates how the use of pMHC thermostability can be used to train an improved model for the prediction of peptide immunogenicity, specifically of cancer neoepitopes. This is particularly relevant for Evaxion’s PIONEERTM, our proprietary AI platform for the rapid discovery and design of patient-specific neoepitopes used to derive immuno-oncology therapies.” PIONEER uses sophisticated algorithms to identify and select tumor-specific mutations that we believe are most likely to generate a de novo T-cell activation and anti-tumor immune response. These tumor-specific mutations, termed neoepitopes, are incorporated into patient-specific immunotherapies. Evaxion is continuously improving the performance of its PIONEER platform in selecting putative neoepitopes by modifying aspects of the underlying algorithms and through the development of novel methods for data generation. Although the stability of pMHC is known to be important, current assays assess this interaction only for a single peptide at a time and in isolation and not in the context of natural antigen processing and presentation. We believe this new method provides a comprehensive and unbiased measure of pMHC stability for thousands of individual ligands detected simultaneously by mass spectrometry. This allows rapid assessment of intra-allelic and inter-allelic differences in pMHC stability and shows profiles of stability that are broader than previously appreciated, facilitating the training of the new model. This assay can be applied to any cells bearing MHC or MHC-like molecules, offering insight into not only the endogenous immunopeptidome, but also that of neoepitopes and pathogen-derived sequences. About EvaxionEvaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer, bacterial diseases and viral infections. Evaxion has developed its AI-immunology core technology to deeply understand the biological processes relevant for engaging the immune system so the Company can harness its powers through novel immunotherapies. Evaxion’s scalable AI-immunology core technology enables broad applicability across diseases with immunological components. With deep insights into the biological processes of the immune system, Evaxion bridges technology, engineering expertise and drug development know-how to bring novel immunotherapies to patients. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase 1/2a clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus) induced skin and soft tissue infections. For more information EvaxionLifeSci Advisors LLCGlenn S. VraniakMary-Ann ChangChief Financial OfficerManaging Directorgvr@email@example.com+1 (513) 476-2669+44 7483 284 853 Source: Evaxion Biotech Forward-looking statement This announcement may contain certain forward-looking statements, including relating to the terms of the proposed offering and the completion of the proposed offering. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; risks associated with the Company’s development work; risks associated with the cost and success of the Company’s product development activities and preclinical and clinical trials; risks related to commercializing any approved pharmaceutical product developed using the Company’s AI platform technology, including the rate and degree of market acceptance of the Company’s product candidates; risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture; risks associated with the Company’s inability to enter into partnerships; risks related to government regulation; risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s ADSs and ordinary shares, risks associated with the pandemic caused by the novel coronavirus known as COVID-19 and other risks and uncertainties affecting the Company’s business operations and financial condition. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
SL Green Realty Corp. (NYSE:SLG), Manhattan’s largest office landlord, today announced it has earned the WELL Health-Safety Rating across its entire 23 million square foot core portfolio, including at One Vanderbilt Avenue, one month after SL Green moved its headquarters into the sky-line defining tower in the heart of East Midtown. The WELL Health-Safety Rating is an evidence-based rating verified through the International WELL Building Institute (IWBI) that focuses on operational policies, maintenance protocols, stakeholder engagement, and emergency plans to address a post-COVID-19 environment.
Hannon Armstrong Sustainable Infrastructure Capital, Inc. ("Hannon Armstrong," or the "Company") (NYSE: HASI), a leading investor in climate solutions, today announced the closing of a $400 million senior unsecured sustainability-linked revolving credit facility (the "Facility"). JPMorgan Chase Bank, N.A. ("JPMorgan"), acted as administrative agent, sole bookrunner, sole lead arranger, and sustainability structuring agent. The Facility is comprised of 10 total participants, including JPMorgan, Bank of America, N.A., Barclays Bank PLC, Credit Suisse AG (New York Branch), KeyBank National Association, Morgan Stanley Senior Funding, Inc., Royal Bank of Canada, Sumitomo Mitsui Banking Corporation, Wells Fargo Bank, N.A., and Goldman Sachs Bank USA.
WeWork, the leading flexible space provider, has announced that it will begin servicing a new economy by now accepting payment in select cryptocurrencies. In partnership with BitPay and Coinbase, the company will expand its flexibility by utilizing cryptocurrency for inbound and outbound transactions.